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Abstract/Background
Identified risk polymorphisms affecting the Jak-STAT3 pathway in patients
with Crohn’s disease could affect TGF-β1 and collagen I expression and in the
pathway’s negative regulator, SOCS3. Genetic factors, however, account for
only ~25% of disease. Epigenetic events also shape gene expression. Recent
experiments showed that autocrine IL-6 production in mesenchymal cells,
subepithelial myofibroblasts (SEMF) and muscle cells, of patients with
fibrostenotic Crohn’s disease causes sustained Jak-STAT3 activity, excess TGFβ1 and Collagen I production and fibrosis. SOCS3 paradoxically decreased in
these cells. We now identify epigenetic mechanisms that silence SOCS3
expression in SEMF of patients with fibrostenotic Crohn’s disease. In a
previous experiment, using isolated SEMF of normal ileum and affected ileum
from patients with each Crohn’s phenotype, inflammatory (Montreal B1),
fibrostenotic (B2) and penetrating (B3), we confirmed decreased SOCS3
protein levels were unique to B2 patients. Expression of miR-19b increased in
SEMF of affected ileum. SOCS3 transcriptional activity decreased after
transfection of miR-19b mimic and increased when antagomiR-19b was
expressed. Epigenetic silencing of SOCS3 in ileal SEMF of patients with
fibrostenotic Crohn’s disease occurs by increased miR-19b mediated
inhibition of SOCS3.

Introduction

• Cytokines, including IL-6, are pivotal modulators of responses in
inflammatory diseases and are secreted by numerous cells including
activated intestinal subepithelial myofibroblasts.
• Binding of IL-6 activates the constitutively associated JAK-1 and JAK2 resulting in cross-phosphorylation and docking sites for STAT3.
Specific STAT3 residues are acetylated and phosphorylated and
STAT3 translocates to the nucleus where it regulates transcriptional
activity, including of TGF-β1 and COL1a1.
• A consensus STAT3 binding element is present in the 5’-UTR
promoter region of the Suppressor of Cytokine Signaling-3 (SOCS3)
gene (1).
• Normally activation by IL-6, via Jak-STAT3, induces expression of
SOCS3, a crucial negative regulator of cytokine-induced Jak-STAT3
signaling.
• We recently demonstrated that in patients with Crohn’s disease with
a Montreal B2 fibrostenotic phenotype, that despite increased
autocrine production of numerous pro-inflammatory cytokines,
particularly IL-6, in mesenchymal cells of affected ileum, there is loss
of the expected upregulation of SOCS3 protein.

Figure 1. SOCS3 expression decreased in affected ileum of
patients with stricturing (Montreal B2) and penetrating (B3)
Crohn’s disease compared to normal ileum in the same patient
as well as non-Crohn’s subjects. The opposite occurred in patient
with inflammatory (B1) Crohn’s disease. Values represent the
mean ± SEM of 5-6 separate experiments. *denotes p<0.05 vs
normal ileum in the same patient.

• In mesenchymal cells, subepithelial myofibroblast (SEMF) and smooth
muscle cells, we observed sustained JAK-STAT3 signaling that accounted
for the excess TGF-β1 and collagen I production from these cells that is a
characteristic pathogenetic mechanism in fibrostenotic Crohn’s disease
(2).
• Epigenetic mechanisms are increasingly recognized as regulators of gene
expression and disease. Genetic factors account for at most 25% of
disease in Crohn’s patients. One important epigenetic process regulating
expression is small non-coding microRNAs (miRs) that target mRNA for
degradation.
• A highly conserved STAT3 binding element is present in the promoter
region of the miR17~92 cluster gene, C13orf25 (3). Position 1561-1568 of
the SOCS3 3' UTR is an 8-mer sequence for miR-19a-5p and miR-19b-5p
binding derived from this cluster (1).
• This work identifies one of three epigenetic mechanisms leading to the
unexpected low levels of SOCS3 expression in patients with fibrostenotic
Crohn’s disease compared to other Crohn’s disease phenotypes.
• SOCS3 expression is silenced in SEMF of patients with fibrostenosis via
increased expression of miR-19a-5p and miR19b-5p that targets Socs3
mRNA for degradation.
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Results: miR-19b regulates SOCS3

Figure A. Hybridization analysis of SOCS3 and miR-19b identified a
conserved 8-mer seed sequences complementary for both hasmiR-19a and hsa-miR-19b at position 1561-1568 of SOCS3 3' UTR.

Methods

Conclusion
• Transcription of miR-19b-5p from the miR-17~92 targets SOCS3 mRNA for
degradation
• The epigenetic events explored in this experiment, miRs, are linked not
only to fibrostenotic Crohn’s disease but also to development of fibrosis in
other organs including the skin, heart, liver, lung, and kidney (4, 5, 6)
• Expression of miRs are altered in the fibroblasts of fibrotic organs
including several members of the paralogous miR17~92 and miR106a~363
clusters, miR-21 and miR-29 (7-11). These resulting epigenomic alterations
impact expression of pro-fibrotic genes such as collagen, TGF-β1, matrix
metalloproteinases and α-smooth muscle actin resulting in their increased
expression and development of fibrosis.
• In summary, identified genetic factors and susceptibility loci account for
only 13.6% of disease variability and no more than 25% of the genetic risk
in patients with Crohn’s disease (12,13). Epigenomic changes can further
contribute to the ‘heritable’ risk of developing fibrostenotic Crohn’s
disease. This data demonstrates one of the mechanisms of epigenetic
silencing of SOCS3 that allow the sustained Jak-STAT3 activity that drives
excess TGF-β1 and collagen expression and characterizes fibrostenotic
Montreal B2 Crohn’s disease.

Methods
• Mesenchymal cells were isolated from Crohn’s disease patients
• Human studies were approved by the VCU Institutional Review Board
• Quantitative real-time PCR used to measure RNA transcripts with miR-19a5p and miR-19b-5p primers
• Results for qRT-PCR were calculated using the 2-∆∆Ct method based on U6
for miR amplification (remains stable across Crohn’s phenotypes
examined)
• Luciferase Reporter Assay was used to measure gene transcription.
• Cells were transfected with anti-miR-19b or pre-miR-19b.
• Statistic Analysis: values represent means + SE of n experiments, where n
represents the number of experiments on cells derived from separate
subjects
• Statistical significance was determined by Student’s t-test for either paired
or unpaired data and was assumed for p<0.05
• Comparison between multiple groups was made using ANOVA with a
Turkey test for post hoc comparisons

Figure B. miR-19a and miR-19b expression was unchanged or decreased
in SEMF of affected ileum in patients with Montreal B1 and B3
phenotype Crohn’s disease, respectively, compared to non Crohn’s
subjects. In contrast, miR-19b levels were significantly elevated in SEMF
of affected ileum compared to normal ileum in patients with B2
fibrostenotic disease. * denotes p<0.05 vs normal ileum.
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Demographics
Age (years)
under 20
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50-59
over 60
Sex
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Race
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Non-Crohn’s Subjects
CD Subjects Montreal Phenotype
B1-non-stricturing, non penetrating
B2-stricturing
L1-ileal 4 (67%)
L2-ileo-colic 2 (33%)
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B3-Penetrating
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9 (38)
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4 (17)
1 (4)
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9 (37)
15 (63)
14 (58)
9 (38)
1 (4)
6 (100)
6 (33)
6 (33)
4 (67)
2 (33)

Figure C. Transcriptional activity of socs3 was decreased in SEMF of
normal ileum of patients with fibrostenosis by transfection of miR-19b5p mimic. Transcriptional activity of SOCS3 in SEMF of affected ileum
was increased by transfection of antagomiR-19b-5p. Transcriptional
activity was measured by dual luciferase-SEAP reporter assay. Values
represent the mean ± SEM of 3-6 separate experiments. * denotes
p<0.05 vs normal ileum (B), or control scrambled miR (C).
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